Neoadjuvant chemoimmunotherapy in non-small cell lung cancer

Project aims/goals
- Comprehensively evaluate the somatic genomic profiles of patients with non-small cell lung cancer (NSCLC) who received neoadjuvant chemoimmunotherapy (NCIT)
- Determine pathological response rates and surgical outcomes in patients treated with NCIT
- Understand the in-vivo change in genomic and transcriptomic landscape post NCIT in order to identify putative biomarkers of response and resistance.
Summary
Patients with resectable, early-stage NSCLC, who were deemed candidates for NCIT were identified from the Glans-Look Database, a province-wide, real world outcomes registry. Tissue samples from surgical resection will be tested through the MOHCCN PR initiative to determine their transcriptomic and genomic profiles. Demographics, disease specific variables, treatment variables, surgical and NCIT treatment outcomes, will be collected.
We will evaluate patient characteristics and treatment response rates in light of the comprehensive genomic profiles of these patients to describe clinical outcomes and identify opportunities for the use of precision therapy in the early-stage NSCLC space.
Anticipated outcomes and impact
Evaluating genomic profiles of patients with NSCLC receiving NCIT may identify early biomarkers of response and resistance to immune checkpoint inhibitor therapies. Real world experiences with a NCIT approach and comprehensive genomic profiling within the early-stage NSCLC population do not exist. While NCIT is increasingly being used to treat patients with early-stage NSCLC, there are currently no biomarkers to identify who would benefit most from this approach or who may require alternative strategies to improve the chances of cure.
Key Researcher
-
Vishal
Researcher
Navani